Temporary mechanical support in fulminant myocarditis: prognostic factors and clinical implications from the FULLMOON study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • Schmidt M
  • Ponnaiah M
  • Huang F
  • Montero S
  • Raimbault V
  • Abrams D
  • Lebreton G
  • Pellegrino V
  • Ihle J
  • Bottiroli M
  • Persichini R
  • Barrionuevo-Sánchez MI
  • Ariza Solé A
  • Ng PY
  • Ching SSW
  • Ayer R
  • Buscher H
  • Biendel C
  • Delmas C
  • Ferreira R
  • Roncon-Albuquerque R Jr
  • L?pez-Sobrino T
  • Bunge JJH
  • Fisser C
  • Franchineau G
  • McCanny J
  • Ohshimo S
  • Sionis A
  • Hernández-Pérez FJ
  • Barge-Caballero E
  • Balik M
  • Muglia H
  • Park S
  • Donker DW
  • Porral B
  • Aïssaoui N
  • Mekontso Dessap A
  • Lesouhaitier M
  • Fried J
  • Jung JS
  • Rosillo S
  • Scherrer V
  • Nseir S
  • Winszewski H
  • Jorge-Pérez P
  • Kimmoun A
  • Diaz R
  • Hekimian G
  • Ammirati E
  • Combes A
  • FULLMOON Study Group

Abstract

BACKGROUND: Temporary mechanical circulatory support (t-MCS) is increasingly used in fulminant myocarditis (FM), yet long-term outcomes and risk factors remain poorly defined. METHODS: From the FULLMOON international cohort (419 adults with suspected FM across 36 centers in 15 countries), 295 patients treated with venoarterial extracorporeal membrane oxygenation (V-A ECMO) and/or Impella were analyzed. The primary endpoint was mortality at 1 year, heart transplantation (HTx), or left-ventricular assist device (LVAD). Multivariate Cox regression identified predictors of adverse outcomes. A propensity score-weighted analysis assessed outcomes based on timing of endomyocardial biopsy (EMB): early (= 2 days), delayed (> 2 days), or none. RESULTS: The median age was 39 years (IQR 28-60), and 55% were female. Myocarditis was confirmed in 204 (69%) of the patients via histology or cardiac MRI. Histological data were available for 151 (51%) of the cohort. One-year mortality was 36%, while 44% died or had an HTx or LVAD. Predictors of worse outcomes were giant cell myocarditis, older age, cardiac arrest at ECMO initiation, and delayed EMB. Delayed EMB was consistently associated with higher mortality, HTx, or LVAD compared to early (HR = 1.55; 95% CI 1.23-1.96; p < 0.01) or no EMB (HR = 1.59; 95% CI 1.26-2.01; p < 0.01). However, event-free survival did not differ significantly between early EMB and no EMB (HR = 1.03; 95% CI 0.80-1.32; p = 0.85). CONCLUSIONS: Despite a relatively young cohort, FM requiring t-MCS is associated with a high 1-year mortality rate. Timely recognition and early referral to specialized ECMO centers before cardiac arrest are critical.

© 2026. Springer-Verlag GmbH Germany, part of Springer Nature.

Datos de la publicación

ISSN/ISSNe:
0342-4642, 1432-1238

INTENSIVE CARE MEDICINE  SPRINGER

Tipo:
Article
Páginas:
240-251
PubMed:
41524796
Factor de Impacto:
0,000 SCImago

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • ECMO; Endomyocardial biopsy; Fulminant myocarditis; Outcomes; Temporary mechanical support

Campos de Estudio

Cita

Compartir